Samsung Bioepis’s Opuviz became the first Eylea biosimilar to be approved in the US. In particular, due to its interchangeability designation, Opuviz can be administered interchangeably with Eylea, increasing its chances of gaining an advantage in the market over its competitors.

According to KoreaBIO on the 21st, the US FDA approved Samsung Bioepis’s Opuviz and the Indian Biocon Biologics's Yesafili as interchangeable biosimilars that can substitute the original macular degeneration treatment Eylea. The approval will allow pharmacies in the US to make substitutions of Eylea at the pharmacy level without an additional physician’s prescription.

The FDA began designating interchangeable